FDA Approves Dupixent (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis Read more
Tavotek Announces a Research Agreement with Genmab for the Development of Bispecific Antibodies Read more
GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio Read more